SCHEMBL9596177

SCHEMBL9596177

CCCCCC(C)CC(C)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.44
ACE2 Q9BYF1 1/20 0.42
CA1 P00915 2/20 0.37
SPHK1 Q9NYA1 1/20 0.37
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.35
DNM1 Q05193 2/20 0.35
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
SMPD1 P17405 2/20 0.33
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCI P41743 1/20 0.33
PRKCE Q02156 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28897844 0.98 ACE2 (0.45) OPRM1ACE2SPHK1LMNADNM1
SCHEMBL11566277 0.92 DNM1 (0.36) OPRM1ACE2LMNADNM1TSHR
SCHEMBL134814 0.87 ACE2 (0.37) OPRM1ACE2LMNADNM1
SCHEMBL4273903 0.84 OPRM1 (0.52) OPRM1ACE2CA1SPHK1LMNA
SCHEMBL7756805 0.81 TSHR (0.46) TSHR
SCHEMBL4272056 0.81 ACE2 (0.52) OPRM1ACE2SPHK1LMNADNM1
SCHEMBL4275206 0.81 ACE2 (0.52) OPRM1ACE2SPHK1LMNADNM1
SCHEMBL4281824 0.81 ACE2 (0.52) OPRM1ACE2SPHK1LMNADNM1
SCHEMBL4275317 0.81 ACE2 (0.52) OPRM1ACE2SPHK1LMNADNM1
SCHEMBL4275509 0.81 ACE2 (0.52) OPRM1ACE2SPHK1LMNADNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122030497-A Fermentation method for cooperatively treating ganoderma lucidum by bacterial enzymes and application of fermentation method in pet food 杭州半边野兽科技有限公司 2026-05-15 CN disclosed
US-20250197341-A1 METHOD FOR INHIBITING CRYSTALLISATION BIOSYNTHIS (FR) 2025-06-19 US disclosed
EP-4387582-A1 METHOD FOR INHIBITING CRYSTALLISATION Biosynthis (FR) 2024-06-26 EP disclosed
CN-117940101-A Method for inhibiting crystallization 碧昂赛恩斯公司 2024-04-26 CN disclosed
CN-106996965-B Rice mould online monitoring system, establishing method and application 华中农业大学 2023-03-31 CN disclosed
WO-2023020979-A1 METHOD FOR INHIBITING CRYSTALLISATION BIOSYNTHIS (FR) 2023-02-23 WO disclosed
CN-110632207-B Method for identifying mold based on volatile gas components and evolution trend thereof 南京财经大学 2022-04-29 CN disclosed
CN-107219827-B Rice food full-industry chain information system, establishment method and application 华中农业大学 2020-06-05 CN disclosed
CN-110632207-A Method for identifying mold based on volatile gas components and evolution trend thereof 南京财经大学 2019-12-31 CN disclosed
CN-207067075-U Rice mould on-line monitoring system 华中农业大学 2018-03-02 CN disclosed
CN-107219827-A The full industrial chain information system of rice food, method for building up and application 华中农业大学 2017-09-29 CN disclosed
CN-106996965-A Rice mould on-line monitoring system, method for building up and application 华中农业大学 2017-08-01 CN disclosed
US-5207838-A Nonhazardous solvent composition and method for cleaning metal surfaces MARTIN MARIETTA ENERGY SYSTEMS, INC. (US) 1993-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197341-A1 METHOD FOR INHIBITING CRYSTALLISATION FASN, SCD5, NFKB2 OPRM1 4200/4885ACE2 449/4885CA1 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.